- Robert W. Baird increased Humana's stock price target to $390.00, indicating potential upside despite a turbulent market day.
- Analyst sentiment is mixed, with Raymond James downgrading Humana to a Market Perform rating, suggesting performance in line with the broader market.
- Humana's management confirmed 2026 financial performance is on track, targeting a pretax margin of at least 3.00% by 2028 through Medicare Advantage margin expansion and operating-cost reductions.
Humana Inc. (NYSE: HUM) is a prominent American health insurance company. It focuses on providing government-sponsored health care plans, with a large part of its business in Medicare Advantage. These are private health plans that are approved by Medicare, a federal program for people aged 65 or older.
On July 30, 2026, the firm Robert W. Baird increased its stock price target for Humana to $390.00 from a previous $205.00. A price target is an analyst's estimate of a stock's future value. At the time, with the stock at $365.89, this new target represented a potential increase of approximately 6.60%.
This update occurred during a turbulent trading day, as highlighted by 247 Wallst. Major market indexes fell, with the S&P 500 declining 1.51% and the Dow Jones Industrials dropping 2.18%. Humana's stock performance was also affected, falling 5.87% for the day to close at $365.89.
However, analyst sentiment is mixed. While Robert W. Baird is optimistic, Raymond James analyst John Ransom downgraded Humana from an Outperform rating to Market Perform. This change suggests an expectation that the stock will perform in line with the general market, rather than exceeding it.
These analyst actions follow Humana's recent Q2 earnings call. Management stated that 2026 financial performance is on track, with a focus on achieving a pretax margin of at least 3.00% by 2028. This business strategy includes planned Medicare Advantage margin expansion in 2027 and ongoing operating-cost reductions.